VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC

Virginia Kaklamani, MD, UT Southwestern Medical Center, Dallas, TX, shares the updated results of the Phase III EMERALD (NCT03778931) trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer. The primary results had demonstrated that elacestrant was superior to standard endocrine therapy. This year at the San Antonio Breast Cancer Symposium (SABCS) 2022, results of the EMERALD trial were presented based on duration of prior CDK4/6i in the metastatic setting. The duration of prior CDK4/6i in the metastatic setting was positively associated with progression-free survival (PFS), the longer the duration of prior CDK4/6i in the metastatic setting, the longer the PFS on elacestrant versus standard of care. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

So the EMERALD trial is a Phase III clinical trial in patients with ER-positive metastatic breast cancer, where patients were randomized to either receive an elacestrant which is an oral selective estrogen receptor down regulator or standard of care endocrine therapy, which was either an aromatase inhibitor or fulvestrant. The primary results in the trial were presented last year showing that elacestrant is superior to standard of care endocrine therapy...

So the EMERALD trial is a Phase III clinical trial in patients with ER-positive metastatic breast cancer, where patients were randomized to either receive an elacestrant which is an oral selective estrogen receptor down regulator or standard of care endocrine therapy, which was either an aromatase inhibitor or fulvestrant. The primary results in the trial were presented last year showing that elacestrant is superior to standard of care endocrine therapy. This year, we’re presenting results based on duration of CDK4/6 inhibitor prior to the enrollment of EMERALD and what we were able to show was that patients who had a longer duration of the CDK4/6 inhibitor had more benefit from an extended use of elacestrant.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter